Clinically reviewed by Dr. Sarah Boss, MD
Chest pain, fainting, a seizure, severe agitation, hallucinations or immediate suicidal danger needs urgent assessment. Do not borrow ADHD medicines, switch products independently or abruptly stop guanfacine or clonidine.
Medication can be one part of treatment for attention-deficit/hyperactivity disorder, or ADHD. The decision is not simply whether to take a stimulant. It involves confirming the diagnosis, identifying the difficulties that need help, considering other health conditions and choosing a plan that can be reviewed. Treatment should support daily life without requiring a person to ignore unwanted effects or abandon practical and psychological support.
Start with a clear assessment
ADHD assessment considers a persistent pattern of inattention and/or hyperactivity-impulsivity, its developmental history and its impact in different settings. A questionnaire can contribute information but is not the whole diagnosis. Sleep problems, anxiety, depression, trauma-related difficulties and substance use can overlap with concentration problems. A careful assessment asks which difficulties have been longstanding and which are new. [1]
Bring examples from education, work, relationships, finances, appointments and everyday routines. School reports or information from someone who knew you earlier may help where available, but the clinical evaluation should explain how the evidence is being interpreted. Trying somebody else’s medicine is not a diagnostic test and carries avoidable risks.
When medication enters the discussion
The role of medication depends on age, the severity of impairment, environmental adjustments, previous support and preferences. NICE recommends age-specific pathways rather than a single rule for children and adults. For adults whose ADHD continues to cause significant impairment after environmental changes have been implemented and reviewed, medication can be considered within a specialist plan. Younger children require a different approach. [1]
Ask what the prescription is intended to improve and what alternatives or additional supports are reasonable. A preference for medication does not remove the need for assessment. A preference not to take it should also be discussed without assuming that the person is unwilling to engage in care. The aim is an informed plan with meaningful review points.
Stimulant options
Methylphenidate and amphetamine-based medicines are the main stimulant families. Lisdexamfetamine is converted to dexamfetamine; other products include dexamfetamine itself, mixed amphetamine salts and dexmethylphenidate. The ingredients, release systems and age indications differ. A brand common in one country may not be routinely available or licensed in another.
NICE lists methylphenidate or lisdexamfetamine as adult first-line pharmacological options and uses a different initial sequence for children and young people. This should not be interpreted as a ranking of every brand worldwide. The stimulant class guide explains why formulation and individual response matter as much as the family name. [1]
Non-stimulant options
Atomoxetine, guanfacine, particular clonidine formulations and viloxazine extended release are non-stimulant options in different treatment systems. They do not share a single safety profile. Some can raise pulse and blood pressure; others can lower them and cause sedation. Licensing, age and the reason for choosing the medicine need to be specified.
Non-stimulants may take longer to assess than stimulants, and they should not be judged solely by how the first dose feels. NICE describes atomoxetine after certain stimulant trials in adults and calls for specialist advice for some less usual choices. The non-stimulant guide separates these options and their stopping precautions. [2]
Agree on functional goals before titration
Titration means adjusting treatment under clinical supervision to find a useful balance between benefit and adverse effects. Goals might include getting through a morning routine, completing essential tasks, following a discussion or managing impulsive spending. Choose a small number that can be observed repeatedly. The target is not to become a different person or remain maximally productive all day.
Keep the record simple enough to use. Note the medicine, actual timing, one or two examples of benefit and important unwanted effects. Include the parts of the day that remain difficult. A scale can support the review, but the clinician should also ask about work, education, relationships, sleep and well-being. An apparent improvement in attention may not outweigh substantial appetite or mood problems.
Match the formulation to the routine
Immediate-release and longer-acting products differ in how they deliver medicine. Some can be opened or dispersed in a particular way; others must remain intact. Never transfer instructions between products based only on a shared ingredient name. Ask the pharmacist to explain the actual package and what to do after a missed dose.
Consider the time when support is needed, ability to swallow the preparation, meals, school arrangements, shift work and sleep. Longer coverage can be useful but is not automatically preferable. If benefit wears off too early or persists too late, describe the pattern. Do not add another preparation, move doses or estimate a conversion without the prescribing team’s instructions.
Physical monitoring and common adverse effects
Baseline assessment includes relevant medical history, other medicines, pulse, blood pressure, weight and cardiovascular assessment. Children also need growth monitoring. Further investigation depends on symptoms, family history and examination. NICE does not recommend routine ECGs for everyone when there is no clinical indication. Monitoring should continue during titration and longer-term treatment. [1]
Stimulants commonly cause appetite reduction, sleep difficulties, headache or stomach discomfort, and can increase pulse and blood pressure. Non-stimulants have different effects, including sedation, digestive symptoms and specific mood warnings. Report persistent problems and explain what they prevent you doing. Do not use alcohol, cannabis or borrowed sleep medicines to offset the effects of ADHD treatment. [3]
Co-occurring anxiety, depression, trauma or bipolar disorder
ADHD treatment may improve some daily difficulties without resolving another condition. The plan should distinguish what belongs to ADHD, what may be an adverse effect and what requires separate care. A new episode of severe anxiety, depression or insomnia should not automatically be treated by increasing the ADHD medicine.
Acute psychotic or manic symptoms require a different clinical response. NICE recommends stopping ADHD medication during an acute psychotic or manic episode and considering any restart only after the episode resolves, based on individual risks and benefits. New hallucinations, severe agitation, immediate suicidal danger or rapidly escalating mood symptoms needs urgent assessment. These are not ordinary indicators that a medicine is beginning to work. [1]
ADHD and substance-use concerns
Discuss alcohol, cannabis, cocaine, nonprescribed stimulants, sedatives and other substances as part of assessment. The pattern can affect diagnosis, interactions, adherence and withdrawal risk. A past or current substance-related problem should be described accurately, and the clinician must consider local product restrictions as well as the broader treatment needs.
Prescription stimulants have misuse and addiction potential. FDA advises secure storage, no sharing and ongoing assessment. Early refills, taking extra doses for work or weight control, or obtaining tablets outside care are important information, not details to hide. An integrated plan should address ADHD and addiction-related needs without assuming one prescription will treat both. [3]
Stopping, treatment breaks and detox
The reason for a treatment interruption matters. A planned review of ongoing need differs from running out, an adverse reaction or stopping after escalating use. Stimulant withdrawal can involve fatigue, low mood, appetite and sleep changes. Guanfacine and clonidine require particular care because abrupt stopping can cause rebound hypertension. There is no single stopping schedule for all ADHD medicines. [4] [5]
ADHD medicines are not general home-detox treatments. Where alcohol or sedative dependence is present, an independent withdrawal assessment may be needed. Severe depression or suicidal thoughts during an interruption needs urgent help. An agreed plan should cover symptom monitoring, practical support, supply and follow-up rather than leaving the person to improvise until the next prescription.
Longer-term review and shared care
NICE recommends that a clinician with ADHD expertise review medication at least annually, including benefit, adverse effects, patient preferences, missed-dose effects and the need for other support. More frequent reviews may be needed during changes or when problems arise. Continuing a prescription should be an active decision, not merely repetition of the previous order. [1]
Before changing services, clarify who prescribes, who monitors and who responds to urgent concerns. Bring the exact product, previous trials, current response and relevant physical measurements. At transitions into adult services or between countries, local licensing and access may change. The medication-review checklist can help organize a concise handover.
Including the person’s priorities in the treatment plan
A young person may value being able to follow a conversation or participate in an activity more than a change in a school score. An adult may prioritize safer driving, managing a household or keeping an important relationship stable rather than increasing work output. Ask what improvement would feel meaningful to the person receiving treatment, then compare that with observations from others.
Different accounts can be useful without one automatically overruling another. A parent may notice smoother mornings while the child describes feeling unusually quiet or losing interest in food. A partner may notice fewer forgotten tasks while the adult reports severe difficulty sleeping. Both benefit and burden belong in the review.
Agree how information will be shared with school, work or another clinician, taking account of the person’s wishes and appropriate clinical responsibilities. A clear plan should support participation, not require unnecessary disclosure of private details. When treatment changes, revisit the original priorities so that the review remains about function and well-being rather than medication use for its own sake.
Frequently asked questions
Will medication cure ADHD?
Medication can reduce symptoms and impairment while it is effective, but it does not erase the diagnosis or replace skills and environmental support. Ongoing need and benefit should be reviewed individually.
Can anxiety mean I should never take a stimulant?
Not necessarily, but the diagnosis, severity, timing and treatment history need assessment. A general rule cannot determine the safest option for an individual, and some product contraindications are specific.
Can I compare doses between brands?
Do not use milligram numbers as a personal conversion system. Ingredient composition, release mechanism and administration differ. Any switch needs a prescriber’s explicit instructions.
What counts as a successful plan?
Meaningful improvement in daily life with an acceptable burden of adverse effects, clear monitoring and support for remaining needs. Stronger stimulation or longer working hours alone is not an adequate measure.
